Rituximab as effective therapy in very severe thrombotic thrombocytopenic purpura (TTP);Rituximab als Effektive Therapie bei Schwerster Thrombotisch Thrombozytopenischer Purpura (TTP)

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 3, 2010, Pages 71-74

  Illner, N ^a   Wolf, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

ADAMTS 13; Plasmapheresis; Rituximab; Thrombotic microangiopathie; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; COOMBS TEST; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; PLASMAPHERESIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; DISEASE COURSE; DRUG ADMINISTRATION; IMMUNOLOGY; KIDNEY FUNCTION TEST; MULTIMODALITY CANCER THERAPY; PLASMA; RETREATMENT; THROMBOCYTE COUNT;

ADAM PROTEINS; ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY FUNCTION TESTS; PLASMA; PLASMAPHERESIS; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RETREATMENT;

EID: 75649087417     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1244819     Document Type: Article

References (17)

1. Basquiera A L., Damonte J C., Abichain P, Sturich A G., Garcia J J. Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange. Ann Hematol 2008 87 321-323
2. Besbas N, Karpman D, Landau D, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006 70 423-431
3. Breslin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009 101 233-238
4. Fakhouri F, Vernant J P., Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005 106 1932-1937
5. Foley S R., Webert K, Arnold D M., et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int 2009 75 Suppl. 112 S55-S58
6. Furlan, M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997 89 3097-3103
7. George J N. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006 354 1927-1935
8. Hagel S, Jantsch J, Budde U, Kalden J R., Eckardt K U., Veelken R. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab. Thromb Haemost 2008 100 151-153
9. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008 23 151-156
10. Levy G G., Nichols W C., Lian E C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 413 488-494
11. Löwenberg M, Stahn C, Hommes D W., Buttgereit F. Novel insights into mechanisms of glucocorticoid action an dthe development of new glucocorticoid receptor ligands. Steroids 2008 73 1025-1029
12. Michael M, Elliott E J., Craig J C., Ridley G, Hodson E M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009 53 259-272
13. Moake J L. Thrombotic microangiopathies. N Engl J Med 2002 347 589-600
14. Rüfer A, Brodmann D, Gregor M, Hovinga J AK, Lämmle B, Wuillemin W A. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. Swiss Med Wkly 2007 137 518-524
15. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007 136 451-461
16. Tsai H M., Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 1585-1594
17. Zheng X L., Sadler J E. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol Mech Dis 2008 3 249-277